NuCana plc (NCNA)
NCNA Stock Price Chart
Explore NuCana plc interactive price chart. Choose custom timeframes to analyze NCNA price movements and trends.
NCNA Company Profile
Discover essential business fundamentals and corporate details for NuCana plc (NCNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Sept 2017
Employees
12.00
Website
https://www.nucana.comCEO
Hugh Stephen Griffith
Description
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
NCNA Financial Timeline
Browse a chronological timeline of NuCana plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$2.65.
Earnings released on 14 May 2026
EPS came in at -$1.25 surpassing the estimated -$2.64 by +52.72%.
Earnings released on 19 Mar 2026
EPS came in at -$1.47 surpassing the estimated -$2.69 by +45.44%.
Earnings released on 13 Nov 2025
EPS came in at -$0.10 surpassing the estimated -$2.69 by +96.28%.
Earnings released on 20 Aug 2025
EPS came in at -$0.16 surpassing the estimated -$2.75 by +94.17%.
Stock split effective on 8 Aug 2025
Shares were split 1 : 200 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 2 Jun 2025
EPS came in at -$126.00 falling short of the estimated -$2.58 by -4.78k%.
Earnings released on 20 Mar 2025
EPS came in at -$64.00 surpassing the estimated -$486.00 by +86.83%.
Earnings released on 25 Nov 2024
EPS came in at -$456.00 falling short of the estimated -$3.47 by -13.04k%.
Earnings released on 15 Aug 2024
EPS came in at -$758.00 falling short of the estimated -$710.00 by -6.76%.
Earnings released on 16 May 2024
EPS came in at -$32.00 surpassing the estimated -$662.00 by +95.17%.
Stock split effective on 16 Apr 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 20 Mar 2024
EPS came in at -$850.00 falling short of the estimated -$650.00 by -30.77%.
Earnings released on 16 Nov 2023
EPS came in at -$800.00 falling short of the estimated -$650.00 by -23.08%.
Earnings released on 16 Aug 2023
EPS came in at -$650.00 surpassing the estimated -$800.00 by +18.75%.
Earnings released on 17 May 2023
EPS came in at -$900.00 falling short of the estimated -$600.00 by -50.00%.
Earnings released on 4 Apr 2023
EPS came in at -$0.07 .
Earnings released on 16 Nov 2022
EPS came in at -$550.00 surpassing the estimated -$650.00 by +15.38%.
Earnings released on 17 Aug 2022
EPS came in at -$450.00 surpassing the estimated -$700.00 by +35.71%.
Earnings released on 2 Jun 2022
EPS came in at -$1.05k falling short of the estimated -$950.00 by -10.53%.
Earnings released on 27 Apr 2022
EPS came in at -$0.14 .
Earnings released on 18 Nov 2021
EPS came in at -$1.05k surpassing the estimated -$1.25k by +16.00%.
Earnings released on 19 Aug 2021
EPS came in at -$1.20k matching the estimated -$1.20k.
NCNA Stock Performance
Access detailed NCNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
